Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ready Mixed Concrete01:26

Ready Mixed Concrete

372
Ready-mixed concrete, also known as pre-mixed concrete, is prepared in a centralized plant and then transported in trucks to construction sites where it is ready for placement. This type of concrete is categorized into central-mixed, truck-mixed (or transit-mixed), and shrink-mixed. Central-mixed concrete is entirely prepared at a plant and moved to the site in agitator trucks that rotate at a speed of 2 to 6 rpm. Truck-mixed concrete, on the other hand, has the ingredients batched at the plant...
372
Yeast Signaling01:28

Yeast Signaling

17.3K
Yeasts are single-celled organisms, but unlike bacteria, they are eukaryotes (cells with a nucleus). Cell signaling in yeast is similar to signaling in other eukaryotic cells. A ligand, such as a protein or a small molecule released from a yeast cell, attaches to a receptor on the cell surface. The binding stimulates second-messenger kinases to activate or inactivate transcription factors that further regulate gene expression. Many of the yeast intracellular signaling cascades have similar...
17.3K
Inflammation01:38

Inflammation

62.1K
Overview
62.1K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

8.6K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
Pinocytosis00:43

Pinocytosis

70.3K
Cells use energy-requiring bulk transport mechanisms to transfer large particles, or large amounts of small particles, into or out of the cell. The cells envelop the particles in spherical membranes called vesicles or vacuoles. Vesicles that transport material into the cell are built from the cell membrane. These vesicles encapsulate external molecules and transport them into the cell in a process called endocytosis.
70.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe Allergic Drug Reaction to Ultrasound Enhancing Agent Resulting in Cardiogenic Shock.

JACC. Case reports·2025
Same author

Can PCI match CABG for multivessel disease? Here is how.

Heart (British Cardiac Society)·2025
Same author

Exploring the Local Structure of Molten NaF-ZrF<sub>4</sub> through In Situ XANES/EXAFS and Molecular Dynamics.

The journal of physical chemistry. B·2025
Same author

An unusual case of acute focal myocarditis caused by gilteritinib, a novel tyrosine kinase inhibitor.

European heart journal. Cardiovascular Imaging·2025
Same author

Clinical Outcomes of Leadless Pacemaker Compared to Right Ventricular Pacing and Conduction System Pacing.

JACC. Clinical electrophysiology·2024
Same author

P014 Postoperative Recurrence in Crohn's Disease Patients Treated with Adalimumab versus Infliximab: A Systematic Review and Meta-Analysis.

The American journal of gastroenterology·2023

Related Experiment Video

Updated: Feb 5, 2026

Elastomeric PGS Scaffolds in Arterial Tissue Engineering
08:35

Elastomeric PGS Scaffolds in Arterial Tissue Engineering

Published on: April 8, 2011

16.1K

Bioresorbable Scaffolds: Ready for a Rematch?

Oludamilola Akinmolayemi1,2, Alexander Levy1,2, Swagata Patnaik3

  • 1Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Weiner Cardiovascular Institute, New York, NY, USA.

Current Cardiology Reports
|February 3, 2026
PubMed
Summary

Bioresorbable vascular scaffolds (BVS) show higher early event rates compared to drug-eluting stents (DES). While long-term outcomes improve, BVS technology requires further development and testing before widespread clinical use.

Keywords:
Bioresorbable scaffoldCoronary arteryCoronary interventionMyocardial ischemiaRevascularization

More Related Videos

Fabrication of a Bioactive, PCL-based "Self-fitting" Shape Memory Polymer Scaffold
09:37

Fabrication of a Bioactive, PCL-based "Self-fitting" Shape Memory Polymer Scaffold

Published on: October 23, 2015

13.5K
Self-reporting Scaffolds for 3-Dimensional Cell Culture
14:49

Self-reporting Scaffolds for 3-Dimensional Cell Culture

Published on: November 7, 2013

13.7K

Related Experiment Videos

Last Updated: Feb 5, 2026

Elastomeric PGS Scaffolds in Arterial Tissue Engineering
08:35

Elastomeric PGS Scaffolds in Arterial Tissue Engineering

Published on: April 8, 2011

16.1K
Fabrication of a Bioactive, PCL-based "Self-fitting" Shape Memory Polymer Scaffold
09:37

Fabrication of a Bioactive, PCL-based "Self-fitting" Shape Memory Polymer Scaffold

Published on: October 23, 2015

13.5K
Self-reporting Scaffolds for 3-Dimensional Cell Culture
14:49

Self-reporting Scaffolds for 3-Dimensional Cell Culture

Published on: November 7, 2013

13.7K

Area of Science:

  • Cardiovascular research
  • Medical device technology

Background:

  • Bioresorbable vascular scaffolds (BVS) offer theoretical advantages over traditional metallic drug-eluting stents (DES).
  • Early randomized controlled trials (RCTs) revealed challenges in clinical application for first-generation BVS.

Purpose of the Study:

  • To review outcomes of early-generation BVS.
  • To provide updates on advancements in newer scaffold technologies and delivery methods.

Main Methods:

  • Analysis of pooled individual patient data from ABSORB studies with 5-year follow-up.
  • Review of outcomes comparing BVS with metallic DES.

Main Results:

  • Pooled data showed higher event rates in the BVS group within the first three years.
  • After three years, BVS event rates were comparable or lower than metallic DES.
  • Current BVS technology is not yet ready for widespread clinical adoption.

Conclusions:

  • Further improvements in BVS technology are necessary.
  • New BVS generations require rigorous testing against metallic DES in large-scale RCTs with long-term follow-up.